Clinical Trial Details

Paradise MI

A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril on Morbidity and Mortality in High Risk Patients Following an AMI

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Acute Myocardial Infarction
Study Type: Interventional
Phase: N/A
Study Start Date: 12/09/2016
Study Completion Date: 07/17/2019

The purpose of this study is to test if LCZ696 taken twice a day, compared to Ramipril taken twice a day, is safe and effective in reducing complications following an acute myocardial infarction (post-AMI), such as death from cardiovascular (CV) causes, hospitalization for heart failure (HF), or outpatient HF.

NCT Number

NCT02924727

Principal Investigator(s)

Geetha Pinto, MD

Sponsor(s)

Novartis Pharmaceuticals

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female